A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses
- PMID: 28863472
- PMCID: PMC5853890
- DOI: 10.1093/infdis/jix201
A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses
Abstract
A nurse who acquired Lassa virus infection in Togo in the spring of 2016 was repatriated to the United States for care at Emory University Hospital. Serial sampling from this patient permitted the characterization of several aspects of the innate and cellular immune responses to Lassa virus. Although most of the immune responses correlated with the kinetics of viremia resolution, the CD8 T-cell response was of surprisingly high magnitude and prolonged duration, implying prolonged presentation of viral antigens. Indeed, long after viremia resolution, there was persistent viral RNA detected in the semen of the patient, accompanied by epididymitis, suggesting the male reproductive tract as 1 site of antigen persistence. Consistent with the magnitude of acute T-cell responses, the patient ultimately developed long-term, polyfunctional memory T-cell responses to Lassa virus.
Keywords: Lassa virus; T cells; biomarkers; human; immunology.
Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Figures







Comment in
-
Moving Lassa Fever Research and Care Into the 21st Century.J Infect Dis. 2017 Jun 15;215(12):1779-1781. doi: 10.1093/infdis/jix206. J Infect Dis. 2017. PMID: 28863471 Free PMC article. No abstract available.
Similar articles
-
Favipiravir and Ribavirin Treatment of Epidemiologically Linked Cases of Lassa Fever.Clin Infect Dis. 2017 Sep 1;65(5):855-859. doi: 10.1093/cid/cix406. Clin Infect Dis. 2017. PMID: 29017278 Free PMC article.
-
Identification of Common CD8+ T Cell Epitopes from Lassa Fever Survivors in Nigeria and Sierra Leone.J Virol. 2020 Jun 1;94(12):e00153-20. doi: 10.1128/JVI.00153-20. Print 2020 Jun 1. J Virol. 2020. PMID: 32269122 Free PMC article.
-
Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein.J Virol. 2000 Mar;74(5):2186-92. doi: 10.1128/jvi.74.5.2186-2192.2000. J Virol. 2000. PMID: 10666248 Free PMC article.
-
Lassa fever: implications of T-cell immunity for vaccine development.J Biotechnol. 1999 Aug 20;73(2-3):207-12. doi: 10.1016/s0168-1656(99)00122-4. J Biotechnol. 1999. PMID: 10486929 Review.
-
Immune responses and Lassa virus infection.Viruses. 2012 Nov 5;4(11):2766-85. doi: 10.3390/v4112766. Viruses. 2012. PMID: 23202504 Free PMC article. Review.
Cited by
-
Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever.Viruses. 2021 Mar 15;13(3):484. doi: 10.3390/v13030484. Viruses. 2021. PMID: 33804206 Free PMC article.
-
Improving the Breadth of the Host's Immune Response to Lassa Virus.Pathogens. 2018 Oct 28;7(4):84. doi: 10.3390/pathogens7040084. Pathogens. 2018. PMID: 30373278 Free PMC article. Review.
-
Diagnostic applications for Lassa fever in limited-resource settings.BMJ Glob Health. 2019 Feb 7;4(Suppl 2):e001119. doi: 10.1136/bmjgh-2018-001119. eCollection 2019. BMJ Glob Health. 2019. PMID: 30899576 Free PMC article.
-
Lassa Virus, but Not Highly Pathogenic New World Arenaviruses, Restricts Immunostimulatory Double-Stranded RNA Accumulation during Infection.J Virol. 2020 Apr 16;94(9):e02006-19. doi: 10.1128/JVI.02006-19. Print 2020 Apr 16. J Virol. 2020. PMID: 32051278 Free PMC article.
-
Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.Vaccine. 2019 Oct 23;37(45):6824-6831. doi: 10.1016/j.vaccine.2019.09.030. Epub 2019 Sep 24. Vaccine. 2019. PMID: 31561999 Free PMC article.
References
-
- McCormick JB, King IJ, Webb PA et al. A case–control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 1987; 155:445–55. - PubMed
-
- McCormick JB. Clinical, epidemiologic, and therapeutic aspects of Lassa fever. Med Microbiol Immunol 1986; 175:153–5. - PubMed
-
- Baize S, Kaplon J, Faure C, Pannetier D, Georges-Courbot MC, Deubel V. Lassa virus infection of human dendritic cells and macrophages is productive but fails to activate cells. J Immunol 2004; 172:2861–9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials